Firm Linked to Trump’s Sons Got Nearly $40 Million in Federal Contracts to Screen for Ebola and Other Diseases

The Trump administration awarded a small biosecurity company, XpresTest, nearly $40 million in federal contracts to screen for Ebola and other infectious diseases, following an investment made by a firm linked to President Donald Trump’s elder sons. The contracts, one for screening Ebola in U.S. airports and the other for responding to disease outbreaks in the Democratic Republic of Congo, are seven times the total value of government contracts the company had received previously.

This marks a new venture for XpresTest, as the company primarily offers spa treatments and biosecurity services at U.S. airports. The CEO of the company's parent, XWELL, stated that the contracts were won through a competitive bidding process and acknowledged the newness of international work for the company. However, experts expressed concern about the government's decision to award such a lucrative contract to a firm without prior experience in Africa.

Brief written by urgent.news from ProPublica's own syndicated text. Machine-written — may contain errors; check the original before relying on it.